An Open-Label Study to Characterize the Pharmacokinetics and Pharmacodynamics of Multiple Oral Doses of PSI-7977 or PSI-352938 in HCV-infected Subjects With Varying Degrees of Hepatic Impairment
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2012
At a glance
- Drugs PSI 938; Sofosbuvir
- Indications Hepatitis C
- Focus Pharmacodynamics; Pharmacogenomic; Pharmacokinetics
- 07 Jun 2012 Actual patients number is 24 as reported by ClinicalTrials.gov.
- 07 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jun 2012 Actual initiation date changed from May 2011 to Jul 2011, as reported by ClinicalTrials.gov.